Meropenem Milpharm

Meropenem, the active ingredient in Meropenem Milpharm, is a carbapenem antibiotic presented as a sterile powder for intravenous use. It is employed to treat severe bacterial infections, particularly those caused by resistant Gram‑negative and Gram‑positive organisms, in hospitalized adult and pediatric patients.

GNH USA supplies Meropenem Milpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company provides reliable cold‑chain logistics, regulatory support, and quality‑assured product to meet the needs of healthcare institutions across continents. Our distribution network ensures timely delivery and compliance with local import requirements.

Meropenem is a broad‑spectrum carbapenem antibiotic indicated for serious infections caused by susceptible bacteria.

- Complicated intra‑abdominal infections: provides bactericidal activity against mixed flora, aiding resolution of severe abdominal sepsis. - Complicated urinary tract infections: eliminates resistant Gram‑negative pathogens, facilitating cure of pyelonephritis and catheter‑associated infections. - Nosocomial pneumonia: treats hospital‑acquired and ventilator‑associated pneumonia caused by multidrug‑resistant organisms. - Septicemia: rapidly clears bloodstream infections by targeting a wide range of Gram‑positive and Gram‑negative bacteria. - Meningitis: penetrates the cerebrospinal fluid to eradicate bacterial meningitis pathogens when susceptibility is confirmed.

Meropenem may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset occurring in many patients. - Diarrhea: loose stools, occasionally leading to dehydration. - Rash: skin erythema or pruritus without systemic involvement. - Headache: transient cephalic discomfort. - Elevated liver enzymes: mild, reversible increases in transaminases. - Injection site pain: discomfort at the intravenous infusion site.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Anaphylaxis: acute, potentially life‑threatening hypersensitivity reaction. - Clostridioides difficile‑associated diarrhea: severe colitis due to gut flora disruption. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: severe skin and mucous membrane reactions. - Renal toxicity: acute kidney injury in susceptible individuals. - Hemolytic anemia: rare immune‑mediated destruction of red blood cells.

Prior to initiating Meropenem therapy, clinicians should evaluate patient-specific factors and monitor for potential complications. - Renal function: assess creatinine clearance and adjust dose in renal impairment. - Hypersensitivity: avoid use in patients with known allergy to β‑lactam antibiotics. - Seizure risk: use caution in patients with a history of epilepsy or CNS disorders. - Concomitant valproic acid: monitor for decreased serum levels and possible seizure breakthrough. - Superinfection: watch for overgrowth of non‑susceptible organisms, including fungi. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Valproic acid: meropenem reduces plasma concentrations, risking loss of seizure control. - Probenecid: may increase meropenem plasma levels, heightening toxicity risk. - Carbapenem‑resistant organisms: co‑administration with other carbapenems offers no benefit and may promote resistance.

Moderate Interactions (Monitor Closely): - Aminoglycosides: combined nephrotoxic potential requires renal function monitoring. - Loop diuretics: may enhance renal clearance, affecting meropenem exposure. - Warfarin: monitor INR as antibiotic therapy can alter anticoagulant effect. - Oral contraceptives: possible reduction in efficacy; advise alternative contraception.